SLGL
Sol-Gel Technologies Ltd.
NASDAQ · Healthcare · Biotechnology · IL
$63.92
+0.17%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$64.78
From 52W high−34.76%
Volume7912.00
Market cap$209.27M
P/E (TTM)—
P/S (TTM)116.6x
Div yield—
Key dataNov 4, 2026
Open
$64.78
From 52W high
−34.76%
Volume
7912.00
Market cap
$209.27M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−9.3x
P/E (TTM)
—
RSI (14)
38.3
MomentumView details →
1D Return
+0.17%
YTD Return
+50.14%
SummaryUpdated Jun 1, 2026
Sol-Gel Technologies Ltd. (NASDAQ:SLGL) is an Israeli clinical-stage specialty pharmaceutical company founded in 1997 and headquartered in Ness Ziona, Israel. The company went public in February 2018 and has built its business around developing and commercializing topical dermatological treatments using a proprietary microencapsulation delivery system. Sol-Gel has successfully brought two FDA-approved products to market - Twyneo for acne treatment and Epsolay for rosacea - while maintaining a robust pipeline of additional dermatological therapies in various stages of clinical development.
Similar companies
Latest newsMore news →
Sol-Gel Technologies announced that the last patient completed the last scheduled study visit in the pivotal Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, with top-line results expected in late November 2026.48d agoSol-Gel Technologies reported its financial results for the second quarter ended June 30, 2026.76d ago